Stockscreener 앱 받기
737.67
2.36%
15.66
전일 마감가:
$722.01
열려 있는:
$735.91
하루 거래량:
170.34K
Relative Volume:
0.44
시가총액:
$45.24B
수익:
$3.06B
순이익/손실:
$1.28B
주가수익비율:
34.64
EPS:
21.2963
순현금흐름:
$447.35M
1주 성능:
+4.97%
1개월 성능:
+7.06%
6개월 성능:
+18.96%
1년 성능:
+40.12%
1일 변동 폭
$732.25
$742.52
1주일 범위
$697.87
$742.52
52주 변동 폭
$510.06
$742.52
알제넥스 NV ADR Stock (ARGX) Company Profile
ARGX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARGX
Argen X Se Adr
|
739.27 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
399.56 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
457.29 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.80 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ONC
Beone Medicines Ltd Adr
|
318.87 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
알제넥스 NV ADR Stock (ARGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-25 | 개시 | RBC Capital Mkts | Outperform |
| 2025-07-08 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-05-13 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2025-03-17 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2025-03-12 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2025-01-17 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2024-11-12 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2024-11-05 | 업그레이드 | Scotiabank | Sector Perform → Sector Outperform |
| 2024-11-01 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-11-01 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2024-10-10 | 재개 | Raymond James | Strong Buy |
| 2024-10-04 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2024-08-06 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2024-07-25 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-07-23 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-12-20 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-12-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-07-31 | 개시 | Scotiabank | Sector Perform |
| 2023-07-24 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-07-17 | 재개 | Evercore ISI | Outperform |
| 2023-06-15 | 개시 | Societe Generale | Sell |
| 2023-05-31 | 개시 | UBS | Buy |
| 2023-04-25 | 개시 | Citigroup | Buy |
| 2023-03-14 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-12-07 | 개시 | William Blair | Outperform |
| 2022-10-12 | 개시 | Oppenheimer | Perform |
| 2022-07-29 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-06-28 | 재개 | Stifel | Buy |
| 2022-05-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-11-29 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-10-29 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-10-28 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-09-23 | 업그레이드 | Redburn | Neutral → Buy |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-23 | 개시 | Deutsche Bank | Hold |
| 2021-07-19 | 재개 | Wolfe Research | Outperform |
| 2021-06-18 | 개시 | UBS | Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-05-10 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2021-04-23 | 개시 | Redburn | Neutral |
| 2021-03-05 | 재확인 | H.C. Wainwright | Neutral |
| 2021-02-02 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-01-04 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-08-19 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2020-07-29 | 개시 | H.C. Wainwright | Neutral |
| 2020-02-10 | 개시 | BofA/Merrill | Buy |
| 2019-11-05 | 개시 | Credit Suisse | Neutral |
| 2019-10-31 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2019-10-22 | 개시 | JP Morgan | Overweight |
| 2019-09-27 | 개시 | Wells Fargo | Market Perform |
| 2019-09-16 | 재개 | Cowen | Outperform |
| 2019-06-28 | 개시 | Robert W. Baird | Outperform |
| 2019-01-18 | 재개 | SunTrust | Buy |
| 2019-01-04 | 개시 | Morgan Stanley | Overweight |
| 2018-12-17 | 개시 | Goldman | Buy |
| 2018-12-14 | 개시 | Wolfe Research | Outperform |
| 2018-06-29 | 개시 | Nomura | Buy |
| 2018-04-09 | 개시 | SunTrust | Buy |
| 2018-01-29 | 재확인 | JMP Securities | Mkt Outperform |
모두보기
알제넥스 NV ADR 주식(ARGX)의 최신 뉴스
Stocks Showing Improving Market Leadership: argenx ADR Earns 84 RS Rating - MSN
Argenx Stock Hits Record High After Reporting 664% Earnings Surge; This Rating Upgraded - Investor's Business Daily
Stocks With Rising Composite Ratings: argenx ADR - MSN
Stocks With Rising Composite Ratings: Argenx ADR - inkl
Argenx Tops Buy Point On Bullish Study, 850 Price Target - Investor's Business Daily
Argenx: study met primary endpoint - AInvest
argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG - GlobeNewswire Inc.
Argenx Shares Rise 0.42% with $190M Volume Ranking 464th Amid Biotech Sector Surge - AInvest
European ADRs Under Pressure: Sector Divergence and Strategic Entry Points - AInvest
Earnings call transcript: Argenx Q2 2025 reports robust earnings beat - Investing.com
Argenx's Growth Fuels Strong Demand for Vyvgart; Pipeline Continues to Develop - Morningstar
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - GlobeNewswire Inc.
This Stock Ran 31% In A Month. Will Upcoming News Revitalize It? - Investor's Business Daily
argenx ADR Earns Relative Strength Rating Upgrade; Hits Key Benchmark - inkl
Argenx NV ADR stock reaches all-time high at 689.13 USD By Investing.com - Investing.com South Africa
Argenx NV ADR stock reaches all-time high at 689.13 USD - Investing.com Nigeria
argenx ADR earnings beat by $3.26, revenue topped estimates - Investing.com South Africa
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Morgan Stanley assumes coverage on argenx stock with Overweight rating - Investing.com
Argenx stock advances as H.C. Wainwright reiterates Buy rating - Investing.com
Argenx stock falls after FDA flags serious risk signal with Vyvgart - Investing.com
argenx SE’s SWOT analysis: biotech stock’s growth potential and challenges - Investing.com
argenx ADR Shows Market Leadership With Jump To 84 RS Rating - Investor's Business Daily
10 Stocks Analysts Are Upgrading Today - Insider Monkey
Argenx Earnings: Vyvgart Delivers Strong Sales Growth; Prefilled Syringe Expands Patient Access - Morningstar
Metric Analysis: Argen X SE ADR (ARGX)’s Key Ratios in the Limelight - DWinneX
Analyzing Ratios: Symbotic Inc (SYM)’s Financial Story Unveiled - DWinneX
Biotech Tumbles. Why Its Sales Beat Wasn't Enough. - Investor's Business Daily
argenx ADR earnings beat by $0.34, revenue topped estimates - Investing.com Nigeria
Crude Oil Gains Over 2%; US Foods Posts Downbeat Earnings - Benzinga
Argenx Stock Extends Rally In A Base As Earnings Loom - Investor's Business Daily
argenx ADR Earns Relative Strength Rating Upgrade - inkl
Argenx stock target holds at $720, H.C. Wainwright affirms Buy rating By Investing.com - Investing.com South Africa
Biotech Leader Surges On 'Best-Case Scenario' For Key Drug - Investor's Business Daily
Guggenheim maintains Buy on Argenx stock, target at $1,100 - Investing.com India
Guggenheim maintains Buy on Argenx stock, target at $1,100 By Investing.com - Investing.com South Africa
Argenx stock target holds at $720, H.C. Wainwright affirms Buy rating - Investing.com India
Stifel maintains $780 target on argenx stock after FDA nod - Investing.com
Stocks To Watch: argenx ADR Sees RS Rating Jump To 91 - Investor's Business Daily
Bernstein double upgrades Argenx to "outperform," raises price target to €755 By Investing.com - Investing.com South Africa
Bernstein double upgrades Argenx to "outperform," raises price target to €755 - Investing.com
Bernstein raises argenx stock rating, hikes target to EUR755 - Investing.com
TD Cowen maintains argenx stock with $761 target, bullish outlook - Investing.com India
TD Cowen maintains argenx stock with $761 target, bullish outlook By Investing.com - Investing.com South Africa
알제넥스 NV ADR (ARGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.09%
2.00%
자본화:
|
볼륨(24시간):